Company intelligence / Profile preview

Ness Therapeutics

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Ness developed highly selective small molecule inhibitors of PTPN2/PTPN1 targeting resistance pathways in cancer. Molecules showed sub-nanomolar potency, >1000-fold selectivity, oral bioavailability, and strong safety in non-clinical models; they enhanced IFNγ responsiveness and tumor growth suppression (preclinical efficacy)

Therapeutic areas: Oncology
Modalities: Small moleculeProtein
Industry: Biotech

Partnerships

Expert Systems (provided AI platform to accelerate drug discovery)

Beyond the preview

Go deeper on Ness Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ness Therapeutics.

Explore the full profile